Biomarker/Pathology Core

$216,530P50FY2015AGNIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Paper 39584156 Paper 39386453 Paper 39379761 Paper 39254167 Paper 39207439 Paper 39173101 Paper 38980643 Paper 38958543 Paper 38949538 Paper 38721926 Paper 38712163 Paper 38641585 Paper 38601916 Paper 38460116 Paper 38441951 Paper 38425303 Paper 38423160 Paper 38418871 Paper 38325732 Paper 38244935 Paper 38194584 Paper 38042785 Paper 37673749 Paper 37592813 Paper 37580727 Paper 37491248 Paper 37474615 Paper 37422964 Paper 37322115 Paper 37260021 Paper 37245492 Paper 37212114 Paper 37066364 Paper 37057867 Paper 37038809 Paper 36997127 Paper 36970907 Paper 36946449 Paper 36840665 Paper 36758620 Paper 36722399 Paper 36710669 Paper 36681388 Paper 36648159 Paper 36628434 Paper 36627206 Paper 36621368 Paper 36617779 Paper 36577280 Paper 36565204 Paper 36564192 Paper 36530083 Paper 36482861 Paper 36394443 Paper 36324086 Paper 36314203 Paper 36308307 Paper 36264254 Paper 36253382 Paper 36251929 Paper 36220593 Paper 36189595 Paper 36178120 Paper 36154934 Paper 36097795 Paper 36093697 Paper 36062452 Paper 36031904 Paper 36031892 Paper 35894783 Paper 35871325 Paper 35842477 Paper 35797594 Paper 35768831 Paper 35699222 Paper 35640459 Paper 35581440 Paper 35551470 Paper 35531707 Paper 35513767 Paper 35444054 Paper 35439098 Paper 35354581 Paper 35351783 Paper 35338450 Paper 35314499 Paper 35253760 Paper 35238936 Paper 35229693 Paper 35213795 Paper 35210353 Paper 35180114 Paper 35128731 Paper 35121671 Paper 35120553 Paper 35103400 Paper 35067420 Paper 35034898 Paper 34966023 Paper 34963063

Abstract

SUMMARY FOR BIOMARKERS/PATHOLOGY CORE The Biomarkers/Pathology Core will provide post-mortem diagnoses and biomarker analyses for patients and control subjects enrolled in the Clinical Core and for other well documented AD cases and controls. The approaches will be state-of-the-art and consistent with 21st century brain banking procedures, and will extend neuropathology core procedures to include targeted mass spectrometric assays to identify and quantitate AD- related biomarkers, as well as to establish induced pluripotent stem cells (iPSCs) from AD patients, innovative approaches which are essential to meet the increasingly sophisticated needs of the AD research community. Thus, the Biomarkers/Pathology Core will provide staff, technical resources, laboratory facilities and expertise for the three main Aims. Aim 1 will establish a Yale Neuropathology Core that will conduct postmortem examinations on Yale-ADRC patients and for other well documented AD cases and controls; and maintain a bank of unfixed frozen and fixed tissue from the ADRC control and patients with AD or other dementing neurodegenerative conditions. Aim 2 will establish and apply quantitative targeted mass spectrometric assays for the analysis of human AD brain samples and biofluids. This will include analysis of unfractionated and fractionated brain tissue, and CSF using MRM and SWATH mass spectrometry methods. Aim 3 will establish procedures for generation of Induced Pluripotent Stem Cells (iPSCs) from human AD patients. The Biomarkers/Pathology Core will closely interact with the other Cores of the Yale ADRC and provide tissue, methodologies and advice to Projects and Pilot Projects users in the ADRC, Yale researchers with an interest in AD, neurodegenerative disease and aging, and with other ADRCs. 1

View original record on NIH RePORTER →